A comprehensive view of Inflammations. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Johnson & Johnson acquires Yellow Jersey for $1.25B to strengthen atopic dermatitis pipeline; NM26 set to enter Phase 2 studies, targeting IL-4Rα and IL-31 pathways
Published: July 11, 2024 by Johnson & Johnson Services Inc.
Johnson & Johnson completes $1.25 billion acquisition of Yellow Jersey Therapeutics; gains NM26, a Phase 2-ready bispecific antibody for atopic dermatitis and other immune diseases
Published: July 11, 2024 by Janssen Pharmaceutical Companies
Johnson & Johnson advances healthcare with immunology focus and new treatments; company’s Apprenticeship Program in Switzerland earns 'Great Start!' Certification from Great Place to Work
Published: July 11, 2024 by Industry Intelligence Inc.
Patent Issued for Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors (USPTO 12018016)
Published: July 11, 2024 by Biotech Business Daily
Neovacs' Board decides not to financially support Pharnext beyond July 15, 2024; Neovacs has already invested over €23 million
Published: July 05, 2024 by Contify Life Science News

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count